Business Segments · D&A
MedSurg and Neurotechnology: — D&A
Stryker MedSurg and Neurotechnology: — D&A decreased by 16.7% to $55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $48M to $55M. Over 4 years (FY 2021 to FY 2025), MedSurg and Neurotechnology: — D&A shows a downward trend with a -18.5% CAGR.
Analysis
StatementSegment
CategoryProfitability
SignalContext dependent
VolatilityStable
First reportedQ1 2019
Last reportedQ1 2026May 11, 2026
Rolls up toD&A
How to read this metric
Rising levels may indicate significant recent capital investment or high levels of acquired intangible assets being written down.
Detailed definition
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the Me...
Peer comparison
Standard accounting metric for capital-intensive industries like medical device manufacturing.
Metric ID:
syk_segment_medsurg_and_neurotechnology_depreciation_and_amortizationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $129.5M | $129.5M | $129.5M | $44.5M | $44.5M | $44.5M | $44.5M | $45.25M | $45.25M | $45.25M | $45.25M | $54M | $56M | $60M | $38M | $48M | $58M | $56M | $66M | $55M |
| QoQ Change | — | +0.0% | +0.0% | -65.6% | +0.0% | +0.0% | +0.0% | +1.7% | +0.0% | +0.0% | +0.0% | +19.3% | +3.7% | +7.1% | -36.7% | +26.3% | +20.8% | -3.4% | +17.9% | -16.7% |
| YoY Change | — | — | — | — | -65.6% | -65.6% | -65.6% | +1.7% | +1.7% | +1.7% | +1.7% | +19.3% | +23.8% | +32.6% | -16.0% | -11.1% | +3.6% | -6.7% | +73.7% | +14.6% |
Range$38M – $129.5M
CAGR-16.5%
Avg YoY Growth-3.5%
Median YoY Growth+1.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Stryker's medsurg and neurotechnology: — d&a?
- Stryker (SYK) reported medsurg and neurotechnology: — d&a of $55M in Q1 2026.
- How has Stryker's medsurg and neurotechnology: — d&a changed year-over-year?
- Stryker's medsurg and neurotechnology: — d&a increased by 14.6% year-over-year, from $48M to $55M.
- What is the long-term trend for Stryker's medsurg and neurotechnology: — d&a?
- Over 4 years (2021 to 2025), Stryker's medsurg and neurotechnology: — d&a has grown at a -18.5% compound annual growth rate (CAGR), from $518M to $228M.
- What does medsurg and neurotechnology: — d&a mean?
- The non-cash expense accounting for the aging of equipment and intangible assets in this segment.